Focuses On Enhancements to Company’s Immunotherapy Assay

Pierian Biosciences will present a poster with new data on ImmunoINTEL, at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer, to be held November 7-11, 2018 at the Walter E. Washington Convention Center in Washington, D.C. The poster, “ImmunoINTEL, a flow cytometry based platform that identifies and quantifies the most critical cell subsets and related functional potential in dissociated solid tumors,” (Poster #114) will be presented in Hall E on Saturday, Nov. 10 from 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m.

“We are excited to present ImmunoINTEL at SITC and the opportunity to discuss with scientists the comprehensive, quantitative profiling of the tumor microenvironment and immune landscape,” says Norman Purvis, executive vice president of research and development for the company. “Our objective is to support biopharma, academic research and clinicians to better stratify patients and guide the selection of immunotherapies.”

 About Pierian Biosciences

Based in Franklin, Tenn., Pierian Biosciences is a privately held life sciences company offering the development and delivery of innovative, treatment-directing information, allowing providers to design patient-specific strategies that improve outcomes, quality of life and lower the cost of cancer care. The company’s technology includes the ChemoINTEL, ImmunoINTEL and PathwayINTEL platforms. Pierian Biosciences has a laboratory in Franklin, Tenn. and business offices in Franklin, Tenn and the UK. For more information visit

Sharing this article